19 October 2017Americas

Amneal and Impax merge to become ‘fifth largest’ generics company

Amneal Pharmaceuticals and Impax Laboratories have agreed to merge, in a deal the companies say will create the fifth largest generics drugs business in the US.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
30 April 2018   The Federal Trade Commission is requiring Impax to divest rights and assets for ten products, as part of a settlement resolving charges that Amneal’s $1.45 billion acquisition would be anti-competitive.
Americas
25 May 2018   A judge has found it unlikely that Impax Laboratories would launch a generic drug before a final court decision in related patent litigation and has dismissed a case against the company.
Americas
11 July 2018   The US Federal Trade Commission has issued a final approval of Amneal’s $1.45 billion acquisition of Impax.

More on this story

Americas
30 April 2018   The Federal Trade Commission is requiring Impax to divest rights and assets for ten products, as part of a settlement resolving charges that Amneal’s $1.45 billion acquisition would be anti-competitive.
Americas
25 May 2018   A judge has found it unlikely that Impax Laboratories would launch a generic drug before a final court decision in related patent litigation and has dismissed a case against the company.
Americas
11 July 2018   The US Federal Trade Commission has issued a final approval of Amneal’s $1.45 billion acquisition of Impax.

More on this story

Americas
30 April 2018   The Federal Trade Commission is requiring Impax to divest rights and assets for ten products, as part of a settlement resolving charges that Amneal’s $1.45 billion acquisition would be anti-competitive.
Americas
25 May 2018   A judge has found it unlikely that Impax Laboratories would launch a generic drug before a final court decision in related patent litigation and has dismissed a case against the company.
Americas
11 July 2018   The US Federal Trade Commission has issued a final approval of Amneal’s $1.45 billion acquisition of Impax.